Analysts think EDSA stock price could increase by 307%
Aug 01, 2024, 6:25 AM
-12.06%
What does EDSA do
Edesa Biotech Inc, based in Markham, Ontario, is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, including their lead candidate EB05 for ARDS. The company, which went public in 2008, is also advancing treatments for allergic contact dermatitis and vitiligo through its EB01 and EB06 drug candidates.
4 analysts think EDSA stock price will increase by 306.81%. The current median analyst target is $20.91 compared to a current stock price of $5.14. The lowest analysts target is $20.20 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
